Fundraising Fox
/Companies
Sign in

Incyclix Bio

Durham, US · Founded 2020 · Delaware LLC · 4 known investors

Find your way into Incyclix Bio

Each arrow is one introduction. Sign up to fill in the first one.

135 people can intro you to Patrick

Ask Kseniya Simpson to introduce you to Patrick Roberts

You →Kseniya · together at Incyclix Bio →Patrick

Sign up to find every way you can get introduced to Incyclix Bio

  • Your email: who you already know at Incyclix Bio, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Incyclix Bio team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up free →Already have an account? Log in

Incyclix Bio develops precision cancer treatments targeting the CDK family of enzymes to restore cell cycle control in tumors, including CDK targets beyond CDK4/6 such as CDK2. The company focuses on drug development for patients with advanced and resistant cancers.

BiotechHealthtech

Founders & leadership

PRPatrick Roberts
Patrick RobertsChief Executive Officer and Co-FounderPatrick Roberts spent over a decade in oncology drug development, including roles in discovery and clinical advancement at G1 Therapeutics, where he contributed to the company's growth from a UNC Chapel Hill incubator stage startup through its public listing. He led translational medicine and nonclinical/clinical teams, and is an inventor on patents supporting multiple clinical-stage compounds in cell cycle targeting.

Board

FN
Fredric N. EshelmanExecutive Officer and member of the Board of Managers.
SS
Sid SubramonyMember of the Board of Managers.
NS
Norman SharplessMember of the Board of Managers.

Investors · 4

Eshelman Ventures, LLClisted by Eshelman Ventures, LLCWilmingtonvia Fred Eshelman · inferred

How we know: Eshelman Ventures, LLC's portfolio page · Not right? Tell us

Hatteras Venture Partnerslisted by Hatteras Venture PartnersResearch Triangle · $500K – $4M

How we know: Hatteras Venture Partners's portfolio page · a partner's Signal profile · Not right? Tell us

HatterasreportedRaleigh

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$26.2M disclosed across 2 rounds · 2022–2025

▶$11.2MraisedAug 2025 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Norman SharplessDirector
  • Fredric N. EshelmanExecutive Officer, Director
  • Patrick RobertsExecutive Officer, Director
Offering amount
$20M
Amount sold
$11.2M
First sale
Aug 2025
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedJul 2023 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Sid SubramonyDirector
  • Patrick RobertsExecutive Officer, Director
  • Fredric N. EshelmanExecutive Officer, Director
Offering amount
$30M
Amount sold
$15M
First sale
Feb 2022
Incorporated
Limited Liability Company, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Incyte CorporationIncyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas. The company focuses on bringing treatments to patients across multiple disease categories.
BicycleBicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers. Beyond oncology, it collaborates with pharmaceutical partners and academic groups to apply the technology to other therapeutic areas including anti-infective, cardiovascular, ophthalmology, dementia, CNS, neuromuscular and respiratory conditions.

Companies working in the same space as Incyclix Bio.

In the news

Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumorsfinance.yahoo.com · Apr 2026Incyclix Bio Raises $11.25M in Series B Extension Fundingfinsmes.com · Aug 2025

Frequently asked questions

What does Incyclix Bio do?
Incyclix Bio develops precision cancer treatments targeting the CDK family of enzymes to restore cell cycle control in tumors, including CDK targets beyond CDK4/6 such as CDK2. The company focuses on drug development for patients with advanced and resistant cancers.
Who are Incyclix Bio's investors?
Incyclix Bio's investors include Cape Fear BioCapital, Eshelman Ventures, LLC, Hatteras Venture Partners, Hatteras.
How much funding has Incyclix Bio raised?
Incyclix Bio has disclosed $26.2M raised across 2 rounds.
Where is Incyclix Bio headquartered?
Incyclix Bio is headquartered in Durham, US.